Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8648206rdf:typepubmed:Citationlld:pubmed
pubmed-article:8648206lifeskim:mentionsumls-concept:C0021051lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C2349001lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C0305065lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C0681850lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C1706203lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C2697811lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C0032594lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C2754943lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C0021006lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C0546816lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C1550501lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C0205151lld:lifeskim
pubmed-article:8648206lifeskim:mentionsumls-concept:C2713304lld:lifeskim
pubmed-article:8648206pubmed:issue6lld:pubmed
pubmed-article:8648206pubmed:dateCreated1996-7-25lld:pubmed
pubmed-article:8648206pubmed:abstractTextHuman immunodeficiency virus (HIV)-infected persons are less likely than are noninfected persons to respond to vaccination with pneumococcal polysaccharides (PPS). Among those who respond, however, similar IgG levels may be achieved. HIV-infected men immunized with pneumococcal vaccine were classified as high- or low-level responders (IgG > or = 1 microgram/mL for > or = 3 of 5 PPS [high] or for < or = 1 PPS [low]). One and 2 years after immunization, geometric mean IgG levels and the percentages of subjects with IgG levels > or = 1 microgram/mL were similar for HIV-infected and for healthy high-level responders (controls) for all PPS except for serotype 8. Among HIV-infected low-level responders, revaccination with a double dose of pneumococcal vaccine did not stimulate IgG responses. Responsiveness of HIV-infected white patients was significantly associated with the Km(1)- negative allotype. These findings support current general recommended guidelines for administering pneumococcal vaccine to HIV-infected persons. Nonresponders will not benefit from revaccination.lld:pubmed
pubmed-article:8648206pubmed:languageenglld:pubmed
pubmed-article:8648206pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648206pubmed:citationSubsetAIMlld:pubmed
pubmed-article:8648206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8648206pubmed:statusMEDLINElld:pubmed
pubmed-article:8648206pubmed:monthJunlld:pubmed
pubmed-article:8648206pubmed:issn0022-1899lld:pubmed
pubmed-article:8648206pubmed:authorpubmed-author:MusherD MDMlld:pubmed
pubmed-article:8648206pubmed:authorpubmed-author:PandeyJ PJPlld:pubmed
pubmed-article:8648206pubmed:authorpubmed-author:GumpD WDWlld:pubmed
pubmed-article:8648206pubmed:authorpubmed-author:Rodriguez-Bar...lld:pubmed
pubmed-article:8648206pubmed:authorpubmed-author:GrooverJ EJElld:pubmed
pubmed-article:8648206pubmed:authorpubmed-author:LahartC JCJlld:pubmed
pubmed-article:8648206pubmed:authorpubmed-author:LackeC ECElld:pubmed
pubmed-article:8648206pubmed:issnTypePrintlld:pubmed
pubmed-article:8648206pubmed:volume173lld:pubmed
pubmed-article:8648206pubmed:ownerNLMlld:pubmed
pubmed-article:8648206pubmed:authorsCompleteYlld:pubmed
pubmed-article:8648206pubmed:pagination1347-53lld:pubmed
pubmed-article:8648206pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:meshHeadingpubmed-meshheading:8648206-...lld:pubmed
pubmed-article:8648206pubmed:year1996lld:pubmed
pubmed-article:8648206pubmed:articleTitleIgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response.lld:pubmed
pubmed-article:8648206pubmed:affiliationMedical Service, VA Medical Center, Houston, TX 77030, USA.lld:pubmed
pubmed-article:8648206pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8648206pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8648206pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8648206lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8648206lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8648206lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8648206lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8648206lld:pubmed